Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).

Affiliation auteurs!!!! Error affiliation !!!!
TitreNab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).
Type de publicationJournal Article
Year of Publication2017
AuteursDubreuil O, Bachet JBaptiste, Hammel P, Desrame J, Meurisse A, Andre T, Debourdeau P, Dauba J, Lecomte T, Seitz JFrancois, Tournigand C, Aparicio T, Meyer VGuerin, Taieb J, Hiret S, Volet J, Monier A, Chibaudel B, Bonnetain F, Louvet C
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume35
Date PublishedFEB 1
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2017.35.4_suppl.350